• About
  • Policies
  • What is openaccess
  • Library
  • Contact
Advanced search
      View Item 
      •   BUIR Home
      • University Library
      • Bilkent Theses
      • Theses - Department of Molecular Biology and Genetics
      • Dept. of Molecular Biology and Genetics - Master's degree
      • View Item
      •   BUIR Home
      • University Library
      • Bilkent Theses
      • Theses - Department of Molecular Biology and Genetics
      • Dept. of Molecular Biology and Genetics - Master's degree
      • View Item
      JavaScript is disabled for your browser. Some features of this site may not work without it.

      Elucidation of Sorafenib resistance mechanisms in hepatocellular carcinoma

      Thumbnail
      Embargo Lift Date: 2019-01-25
      View / Download
      1.3 Mb
      Author
      Boyacıoğlu, Zeynep
      Advisor
      Göktuna, Serkan İsmail
      Date
      2018-07
      Publisher
      Bilkent University
      Language
      English
      Type
      Thesis
      Item Usage Stats
      178
      views
      102
      downloads
      Abstract
      Hepatocellular Carcinoma (HCC) is the sixth most common type of cancer and the second leading cause of cancer-related deaths worldwide. Currently, Sorafenib is the only approved first-line treatment option for unresectable advanced HCC patients. Although Sorafenib can be beneficial for some patients, overall survival can only be extended for 4 months. One of the main reasons is the development of Sorafenib resistance. Many studies have been conducted to decipher the mechanisms underlying this drug resistance, yet much more still awaits for elucidation. This study suggests a novel involvement of a player, an antiviral kinase, which was previously described as an oncogenic protein. Strikingly in our investigation, Sorafenib resistance seems to be caused by the loss of this interferon related kinase. This protein expression is ablated in Sorafenib resistant Hep3B cell line. Loss of this protein by shRNA confers Sorafenib resistance to naïve Hep3B cells. Reversely, protein rescue can re-sensitize these resistant cells to Sorafenib. We also report in this work for the first time that this Sorafenib resistant Hep3B cell line exhibits partial EMT signature. Over all, this study paves way for further studies investigating the implication of this antiviral protein in Sorafenib resistance mechanism in HCC.
      Keywords
      HCC
      Sorafenib Resistance
      Hep3B
      Oncogenic Antiviral Proteins
      Permalink
      http://hdl.handle.net/11693/47682
      Collections
      • Dept. of Molecular Biology and Genetics - Master's degree 135
      Show full item record

      Browse

      All of BUIRCommunities & CollectionsTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartmentsThis CollectionTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartments

      My Account

      Login

      Statistics

      View Usage StatisticsView Google Analytics Statistics

      Bilkent University

      If you have trouble accessing this page and need to request an alternate format, contact the site administrator. Phone: (312) 290 1771
      Copyright © Bilkent University - Library IT

      Contact Us | Send Feedback | Off-Campus Access | Admin | Privacy